Oslo University Hospital
The Paediatric Clinical Trial Unit (P-CTU) is a part of Department of Pediatric Research (PFI) in the Division of Paediatric and Adolescent Medicine at Oslo University Hospital.
The P-CTU was established in 2015 and is located within the Paediatric departments at both Ullevål and Rikshospitalet. It comprises a total of five treatment and observation rooms equipped with advanced monitoring systems, as well as laboratory facilities for sample processing at both locations. The laboratory at PFI is well equipped for advanced biobanking and sample processing. The unit also has access to inpatient beds at the Department of Paediatric Oncology and Haematology. Its central location ensures close proximity to clinical services and facilitates seamless collaboration with inpatient wards and clinical personnel.

Our staff consists of three full-time study coordinators, six research nurses (equivalent to four full-time positions), and three study physicians in part-time positions (all holding a PhD and one professor). We also have a full-time biobank technician, as well as a data manager and administrative support. In addition, we are cooperating closely with Primary Investigators (PI) within most fields of paediatric medicine and also other departments treating children at Oslo University Hospital. Thus, P-CTU has the expertise, capacity, and infrastructure to conduct clinical trials on children within most medical specialties.
In 2025, the P‑CTU was involved in the conduct of 52 clinical studies, including 35 industry‑sponsored trials and 17 academic studies.
Ongoing studies in Oslo
| Prosjekt | Status | Sykehus |
|---|---|---|
| A phase 3 randomized, open-label induction, double-blind maintenance, parallel-group, multicenter protocol to evaluate the efficacy, safety and pharmacokinetics of Guselkumab in pediatric participants with moderately to severely active ulcerative colitis (Quasar Jr) | Pågår | |
| Master protocol: A phase 3, multicenter, randomized, platform study of p19 inhibition of the IL-23 pathway to establich efficacy in pediatric Crohn`s disease. A study of Guselkumab in pediatric participants with moderately to severely active Crohn`s disease (Macaroni). | Pågår | |
| Master protocol: A phase 3, multicenter, randomized, platform study of p19 inhibition of the IL-23 pathway to establich efficacy in pediatric Crohn`s disease. ISA title: A phase 3, multicenter, randomized, clinical study to evaluate Mirikizumab in pediatric Crohn`s diseases (Macaroni). | Pågår | |
| INSTAR: Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezing | Pågår | |
| POPART: Prophylactic oropharyngeal surfactant for preterm infants: a randomised trial | Ferdig | |
| A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control | Ferdig |